<DOC>
	<DOC>NCT01343186</DOC>
	<brief_summary>This study is aimed to study the pharmacokinetic characteristics(e.g. AUC, Cmax, Tmax) of Ypeginterferon alfa-2a and interferon biomarkers(e.g. 2,5-OAS, neopterin) after single dose at different levels.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Healthy subjects Age between 18 and 45, inclusive Body mass index(BMI)between 19 and 26, inclusive Sign informed consent Women of pregnant or lactation Known hypersensitivity to interferon or any other components of the study drug History of mental disease or genetic disease History of diabetes mellitus, thyroid disease, cancer, autoimmune disease, organ transplant Significant disease in heart, liver, kidney, lung or any other major organs Alcoholic, smokers or drug abusers Blood donation, or massive blood loss due to injury or surgery within 3 months Other conditions which in the opinion of the investigator preclude enrollment into the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Peginterferon</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
</DOC>